Cal­lid­i­tas claims mid-stage win for rare liv­er dis­ease drug

Cal­lid­i­tas Ther­a­peu­tics’ NOX en­zyme in­hibitor suc­ceed­ed in a Phase 2b tri­al in peo­ple with a rare liv­er dis­ease that fea­tures in­flam­ma­tion and in­jury in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER